Lynch Henry T, Kaurah Pardeep, Wirtzfeld Debrah, Rubinstein Wendy S, Weissman Scott, Lynch Jane F, Grady William, Wiyrick Sara, Senz Janine, Huntsman David G
Department of Preventive Medicine and Public Health, Creighton University School of Medicine, Omaha, Nebraska 68178, USA.
Cancer. 2008 Jun 15;112(12):2655-63. doi: 10.1002/cncr.23501.
A subset of patients with diffuse gastric cancer harbor deleterious cancer-causing germline mutations in the type 1 E-cadherin (epithelial) gene (CDH1), which predisposes to the autosomal dominantly inherited hereditary diffuse gastric cancer (HDGC) syndrome. These mutations are associated with a 70% life-time risk for diffuse gastric cancer (DGC) and an additional 40% risk for lobular breast cancer in women. Management options for unaffected mutation carriers include prophylactic total gastrectomy.
Four HDGC pedigrees from a cohort of 56 CDH1 mutation-positive families were subjected to further analysis. Cancer diagnoses, whenever possible, were verified with pathology reports and/or slides/tissue block review. Genetic counseling for family members covered the natural history of HDGC, the pros and cons of mutation testing, the lack of effective screening procedures available to CDH1 mutation-positive individuals, and the option for them of prophylactic total gastrectomy.
Within the 4 families, carrier testing for mutations in the CDH1 gene was carried out on 52 individuals, including 25 individuals who were positive for mutation. Prophylactic gastrectomies were performed on a total of 17 individuals from 3 of the families, including 11 first cousins from 1 of the families. Occult DGC was diagnosed in gastrectomy specimens from 13 of 17 individuals (76.5%). During follow-up questioning, each of the 11 cousins stated that the decision for the prophylactic procedure was the "right one" for them.
Unaffected mutation carriers from HDGC families face difficult decisions and can be assisted best through education and interactions with counseling by an informed multidisciplinary team.
一部分弥漫性胃癌患者在1型E-钙黏蛋白(上皮)基因(CDH1)中携带有害的致癌种系突变,这易导致常染色体显性遗传的遗传性弥漫性胃癌(HDGC)综合征。这些突变与弥漫性胃癌(DGC)70%的终生发病风险相关,在女性中还与小叶乳腺癌40%的额外发病风险相关。未受影响的突变携带者的治疗选择包括预防性全胃切除术。
对56个CDH1突变阳性家族队列中的4个HDGC家系进行进一步分析。尽可能通过病理报告和/或玻片/组织块复查来核实癌症诊断。为家庭成员提供的遗传咨询涵盖HDGC的自然病史、突变检测的利弊、CDH1突变阳性个体缺乏有效的筛查程序,以及他们选择预防性全胃切除术的情况。
在这4个家族中,对52人进行了CDH1基因突变携带者检测,其中25人突变呈阳性。来自3个家族的共17人接受了预防性胃切除术,其中包括来自1个家族的11对堂兄弟姐妹。在17例接受胃切除术的患者中,有13例(76.5%)的胃切除标本中诊断出隐匿性DGC。在随访询问中,11对堂兄弟姐妹中的每一个人都表示,预防性手术的决定对他们来说是“正确的”。
HDGC家族中未受影响的突变携带者面临艰难的决策,通过由知识渊博的多学科团队进行教育和咨询互动,能为他们提供最好的帮助。